

Use of Tobacco Cessation Aids and Likelihood of Smoking Cessation: a French Population-Based Study

Mathilde Fekom^{1*}, Tarik El Aarbaoui³, Romain Guignard², Raphaël Andler², Guillemette Quatremère², Simon Ducarroz¹, Viêt Nguyen-Thanh², Maria Melchior¹

¹INSERM, Sorbonne University, Team of Social Epidemiology (ERES), Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Paris, France,

²Santé publique France, the National Public Health Agency, Saint Maurice, France

³EpiDermE, Université Paris Est Créteil, Créteil, France

*corresponding author: mathilde.fekom@iplesp.upmc.fr

International Scientific Conference on E-cigarette, December 2022



Introduction

Sustained tobacco cessation is associated with **psychological, social** and **environmental** factors ⇒ challenging goal to achieve

Although research suggests that e-cigarettes are safer than traditional cigarettes, the level of **risk reduction** is still being discussed:¹

- (+) Suitable substitute for traditional cigarettes to **avoid nicotine withdrawal symptoms**²
- (-) **Enhance nicotine dependence**³ and therefore reduce the odds of successful smoking cessation in the long term

Objective: evaluate effective ways of initiating and maintaining tobacco cessation **in a real-life** rather than an experimental setting




¹David J K Balfour et al. “Balancing Consideration of the Risks and Benefits of E-Cigarettes”. In: *American Journal of Public Health* 111 (9 2021), pp. 1661–1672

²J Hartmann-Boyce et al. “Electronic cigarettes for smoking cessation”. In: *Cochrane Database of Systematic Reviews* (9 2021)

³Ruifeng Chen et al. “Use of Electronic Cigarettes to Aid Long-Term Smoking Cessation in the United States: Prospective Evidence From the PATH Cohort Study”. In: *American Journal of Epidemiology* 189 (12 Jan. 2020), pp. 1529–1537

Population

Data: The 2017 **French Health Barometer**, a representative general population telephone survey from Santé publique France



Cessation aid type



(a) e-cigarette



(b) NRT products



(c) Medication

Exposure – Type of tobacco cessation aid used to try to quit smoking:⁴

- none (reference)
- e-cigarette
- NRT
- e-cigarette & NRT
- other

⁴R Guignard et al. “Smoking Quit Attempts, Use of Cessation Help, and Smoking Abstinence: a Retrospective Analysis of Santé Publique France Health Barometer 2017”. In: *Bull Epidémiol Hebd.* 2021;(1):2-11. (2021)

Tobacco smoking cessation



Outcome – Tobacco smoking cessation:

Three study outcomes corresponding to participants' smoking status **6, 12 and 24 months** after the smoking cessation attempt reported:

- smoker (reference)
- former smoker

The 3 outcomes yielded samples of respectively $N = 2,783$, $N = 1,947$ and $N = 1,079$ participants.

Include covariates

Covariates(X): sex, age, occupational grade, work status, highest level of education, income, etc..

Regression: Weighted logistic regression models controlled for **propensity scores**:⁵

$$PS = \mathbb{P}(\text{exposure} = \text{"e-cig"} | \mathbf{X}) \quad (1)$$

computed with the Gradient Boosting Machine (GBM) algorithm⁶ a nonparametric method allows for complex and non-linear relationship between input variables.

The different exposure groups were quite different → we used the **overlap weighting** (OW)⁷ instead of the more standard inverse probability weighting (IPW)

⁵Fan Li et al. "Balancing Covariates via Propensity Score Weighting". In: *Journal of the American Statistical Association* 113 (521 2018), pp. 390–400

⁶Jerome H. Friedman. "Greedy function approximation: A gradient boosting machine.". In: *The Annals of Statistics* 29.5 (2001), pp. 1189–1232

⁷Yunji Zhou et al. "Propensity score weighting under limited overlap and model misspecification". In: *Statistical Methods in Medical Research* 29 (12 2020). PMID: 32693715, pp. 3721–3756

Socio-demographic characteristics

	None	E-cigarette	NRT	E-cig. & NRT	Other	p
N	1716	430	334	95	209	
Age (mean (SD))	39.06 (14.19)	40.54 (12.33)	46.78 (13.24)	45.16 (12.80)	41.69 (13.24)	<0.001
Work Status (%)						<0.001
Employed	1051 (61)	298 (69)	196 (59)	68 (72)	138 (66)	
Student	121 (7)	23 (5)	8 (3)	1 (1)	17 (8)	
Out-of the labour force	395 (23)	81 (19)	71 (21)	21 (22)	33 (16)	
Retired	148 (9)	27 (6)	59 (18)	4 (5)	22 (10)	
Occupational grade (%)						0.136
Worker	421 (25)	84 (20)	84 (25)	30 (31)	43 (21)	
Supervisor/office employee	828 (48)	226 (53)	146 (44)	44 (46)	105 (50)	
Executive	166 (10)	57 (13)	54 (16)	7 (7)	27 (13)	
Other	27 (2)	7 (2)	1 (0)	0 (0)	4 (2)	
Not working	274 (16)	55 (13)	48 (15)	14 (15)	29 (14)	
Income (%)						<0.001
1st tercile	801 (47)	147 (34)	123 (37)	37 (39)	69 (33)	
2nd tercile	545 (32)	161 (37)	121 (36)	33 (35)	75 (36)	
3rd tercile	370 (22)	122 (28)	90 (27)	24 (26)	65 (31)	
Relationship status = Single (%)	1085 (63)	246 (57)	175 (52)	55 (58)	126 (60)	0.017

All headcounts and percentages were weighted by margin calibration.

Behavioral and health-related characteristics

	None	E-cigarette	NRT	E-cig. & NRT	Other	p
Negative life event = yes (%)	729 (42)	198 (46)	172 (52)	52 (55)	92 (44)	0.040
Physical activity* (%)						0.046
Never	507 (30)	126 (29)	130 (39)	26 (27)	54 (26)	
Monthly/annually	218 (13)	52 (12)	48 (14)	19 (20)	33 (16)	
Weekly	990 (58)	252 (59)	156 (47)	50 (53)	122 (58)	
Chronic disease* = yes (%)	547 (32)	163 (38)	151 (45)	52 (55)	72 (34)	<0.001
Psychotropic medication = yes (%)	613 (36)	180 (42)	178 (53)	47 (49)	99 (47)	<0.001
Social support* (%)						0.020
Below 3	419 (24)	73 (17)	77 (23)	30 (32)	40 (19)	
3 to 5 people	686 (40)	199 (46)	149 (45)	38 (40)	108 (52)	
6 and above	610 (36)	158 (37)	109 (33)	27 (28)	61 (29)	

All headcounts and percentages were weighted by margin calibration. * Imputed with mice


Tobacco-related characteristics

	None	E-cigarette	NRT	E-cig. & NRT	Other	p
Age of regular smoking initiation* (mean (SD))	19.36 (4.67)	18.56 (4.26)	19.25 (4.73)	18.81 (3.59)	18.67 (3.78)	0.020
Nb quit attempts* (mean (SD))	3.60 (8.19)	3.81 (7.04)	3.75 (7.81)	5.12 (5.75)	3.55 (4.68)	0.151
Cessation type* = Progressive (%)	398 (23)	137 (32)	90 (27)	31 (33)	41 (20)	0.005
Smoking status = Former smoker (%)	573 (33)	188 (44)	100 (30)	44 (47)	82 (39)	0.001

All headcounts and percentages were weighted by margin calibration. * Imputed with mice

Regression results

Tobacco cessation – 0: smoker (ref.), 1: former smoker



Discussion

Main findings – While e-cigarette use is associated with both **short and medium-term** transition from being a smoker to being a former smoker, its protective effect on a **longer-term** remains **uncertain**.

Strengths and limitations –

- (-) retrospective assessment → recall bias (limit to 4 years preceding the survey)
- (-) conducted in 2017 and smoking patterns may have somewhat changed since
- (-) could not control for the level of tobacco consumption because of the survey design
- (+) nationally representative sample of the French population
- (+) conducted in real life conditions → easier to generalize
- (+) using a recent method, the overlap weighting, that helps leaning towards a study design in which exposure is more randomized

Findings' interpretation

The use of an **e-cigarette** → associated with tobacco cessation, while this does not appear to be the case for **exclusive NRT** use in our sample.

Possible explanations –

- 1) vaping resembles smoking and might therefore reduce the need to smoke tobacco while maintaining a somewhat familiar gesture
- 2) smokers tend to under-report their tobacco consumption → under-dosed NRT prescription, while vapers are able to adjust their nicotine intake more easily
- 3) NRT users are heavier smokers than e-cigarette users → not controlling for heaviness of smoking might lead to stronger residual confounding for NRT users
- 4) compliance with NRT prescription is not always guaranteed

Conclusion – Other effective ways to increase the likelihood of long-term smoking abstinence include **behavioral counselling** and **financial incentives**⁸ ⇒ combine **counselling** with **self-help approaches** whenever possible.

⁸Ivan Berlin et al. “Financial incentives for smoking cessation in pregnancy: multicentre randomised controlled trial”. In: *BMJ* 375 (Dec. 2021), e065217